OBX
Obsidian Therapeutics, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Aug 3 Obsidian Therapeutics filed an 8-K with a lease amendment and a risk…
- E Aug 17 Trading halt: Halt Resumed: OBX — trading resumed after LUDP (Volatility…
- X Aug 31 Short interest jumps 125.6% to 81.5K
- A Sep 9 William Blair initiates
- R Sep 10 Obsidian Therapeutics' S-1 registration statement was declared effec…
- X Sep 15 Short interest jumps 210.7% to 253.1K
- A Sep 22 Leerink Partners initiates
- X Sep 30 Short interest jumps 249.5% to 884.5K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- AnalystsBULLISH
8 of 9 rate it Buy or better. Every target is above the price.
- TrendDOWNTREND
12% below its 50-day average.
The Street
9 analystsPrice is below the lowest target. Median implies +203%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 22, 2026 | Leerink Partners INITIATE | Outperform |
| Sep 9, 2026 | William Blair INITIATE | Outperform |
| Aug 18, 2026 | LifeSci Capital INITIATE | Outperform |
| Aug 5, 2026 | Piper Sandler INITIATE | Overweight |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 3, 2026 | Jagasia Madan Chief Executive Officer | AWARD | 37,653 sh |
| Aug 3, 2026 | Norkunas Matthew Director | AWARD | 37,653 sh |
| Aug 3, 2026 | ROSS ROBERT W. Director | AWARD | 37,653 sh |
| Aug 3, 2026 | Hagen Heidi Director | AWARD | 37,653 sh |
| Aug 3, 2026 | Barrett Peter Director | AWARD | 37,653 sh |
| Aug 3, 2026 | Fardis Maria Director | AWARD | 37,653 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.42 | -$0.47–-$0.38 | +28.8% | $0.00 |
| Next Q | -$0.51 | -$0.61–-$0.41 | +32.9% | $0.00 |
| Current FY | -$1.82 | -$2.62–-$1.00 | +26.3% | $0.00 |
| Next FY | -$2.79 | -$3.85–-$2.13 | +6.7% | $0.00 |
Short side
FINRA· Oct 15, 2026| Aug 17, 2026 | Volatility Pause | Resumed |
| Aug 13, 2026 | Volatility Pause | Resumed |
| Aug 13, 2026 | Volatility Pause | Resumed |
| Aug 10, 2026 | Volatility Pause | Resumed |
| Aug 5, 2026 | Volatility Pause | Resumed |
SecBot reports
13 filings · 1 bullish · 1 bearish · 11 neutral- NEUTRAL SC 13GOct 5, 2026
Paradigm BioCapital Advisors LP has filed a Schedule 13G disclosing a 6.6% passive stake in…
Paradigm BioCapital is a healthcare-dedicated fund, and its 6.6% stake adds to the roster of sophisticated biotech investors accumulating Obsidian shares. Monitor for any future conversion to a 13D…
- BULLISH EFFECTSep 10, 2026
Obsidian Therapeutics' S-1 registration statement was declared effective by the SEC on September…
The S-1 effectiveness signals that OBX's IPO is imminent — likely pricing within 1-2 trading days. Traders should watch for the final prospectus (424B4) which will disclose the offering price and…
- NEUTRAL 3Aug 3, 2026
Peter Barrett, Ph.D., a director at Obsidian Therapeutics, filed an initial Statement of…
This is a routine director onboarding filing with no trading or financial implications. No action required.
- NEUTRAL 3Aug 3, 2026
Maria Fardis, Ph.D. filed a Form 3 initial statement of beneficial ownership with Obsidian…
This is a routine initial ownership filing with no trading activity or change in company outlook. Monitor for future Form 4 filings for any open-market purchases or sales by the insider.
All OBX filing & press-release reports (13)
- SC 13G reportOct 5, 2026
- EFFECT reportSep 10, 2026
- 3 reportAug 3, 2026
- 3 reportAug 3, 2026
- 3 reportAug 3, 2026
- 3 reportAug 3, 2026
- 3 reportAug 3, 2026
- 3 reportAug 3, 2026
- 8-K reportAug 3, 2026
- EFFECT reportJul 6, 2026
- S-4/A reportJul 2, 2026
- S-4/A reportJun 30, 2026
- S-4/A reportJun 24, 2026